Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 701–800 of 1,002
Are scientists a workforce? – Or, how Dr. Frankenstein made biomedical research sick
Lazebnik, Y. A. (2015) · EMBO Reports · doi:10.15252/embr.201541266 · Cited by 23
“The Eroom law states that the number of drugs approved by the FDA has halved every 9 years since 1950 [7].”
BackgroundApplications of CRISPR genome editing technology in drug target identification and validation
Lu, Q., Livi, G. P., Modha, S. S., Yusa, K., Macarrón, R., & Dow, D. J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1317244 · Cited by 28
“However, the translation of this wealth of knowledge and technologies to new drug approvals has been disappointing [8, 9].”
BackgroundThree Paths to Drug Discovery in Psychiatry
Berk, M., & Nierenberg, A. A. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14070858 · Cited by 21
Benchmarking 3D Structure-Based Molecule Generators
Sanjrani, N., Coupry, D. E., Pogány, P., Palmer, D. S., & Pickett, S. D. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01020 · Cited by 24
Lalu, M. M., Fergusson, D. A., Cheng, W., Avey, M. T., Corbett, D., Dowlatshahi, D. D., Macleod, M. R., Sena, E. S., Moher, D., Shorr, R., et al. (2019) · F1000Research · doi:10.12688/f1000research.15869.1 · Cited by 21
Buchwald, P. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.898035 · Cited by 20
“This is probably best illustrated by the fact that the number of new drugs approved by the United States Food and Drug Administration (FDA) that were developed per $1 billion of R&D spending in the drug industry (inflation-adjusted) has been decreasing exponentially since 1950, being steadily halved about every 9 year…”
BackgroundQian, D., Wang, Q., Lin, S., Li, Y., Gu, X., Xia, C., Xu, Y., Zhang, T., Li, Y., Wu, Q., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24378-0 · Cited by 20
A Microfluidic Organ-On-A-Chip: Into the Next Decade of Bone Tissue Engineering Applied in Dentistry
Syahruddin, M. H., Anggraeni, R., & Ana, I. D. (2023) · Future Science OA · doi:10.2144/fsoa-2023-0061 · Cited by 20
Nanomedicines against Chagas disease: a critical review
Morilla, M. J., Ghosal, K., & Romero, E. L. (2024) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.15.30 · Cited by 21
DrugDiff: small molecule diffusion model with flexible guidance towards molecular properties
Oestreich, M., Merdivan, E., Lee, M., Schultze, J. L., Piraud, M., & Becker, M. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-00965-x · Cited by 28
“The drug development process has become increasingly unsustainable over the last years, with the ratio of product yield to development costs becoming more and more unfavourable [1–4].”
Neural stem cells as tools for drug discovery: novel platforms and approaches
Gorba, T., & Conti, L. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.805199 · Cited by 21
“In the past two decades, the pharmaceutical industry has seen itself challenged to effectively address the ever-larger looming issue of a widening productivity and innovation gap [78,95].”
BackgroundThe penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
Lachmann, P. J. (2012) · QJM · doi:10.1093/qjmed/hcs148 · Cited by 20
Allosteric Modulation of G Protein-Coupled Receptors: An Emerging Approach of Drug Discovery.
Wild, C., Cunningham, K. A., & Zhou, J. (2014) · PubMed · Cited by 20
Systematically Prioritizing Candidates in Genome-Based Drug Repurposing
Challa, A. P., Lavieri, R. R., Lewis, J. T., Zaleski, N. M., Shirey-Rice, J. K., Harris, P. A., Aronoff, D. M., & Pulley, J. M. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2019.950 · Cited by 20
Drug Repurposing in Oncology: Current Evidence and Future Direction
Zhang, Z., Ji, J., & Liu, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200820124111 · Cited by 22
Zhao, X., Xu, Y., Viel, J. H., & Kuipers, O. P. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00161 · Cited by 20
2021 in review: FDA approvals of new medicines
Kinch, M. S., Kraft, Z., & Schwartz, T. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.04.010 · Cited by 20
Vlasakakis, G., Comets, E., Keunecke, A., Gueorguieva, I., Magni, P., Terranova, N., Pasqua, O. E. D., de Lange, E. C. M., & Kloft, C. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.16 · Cited by 20
Hamid, A. R., & Tran, Q. N. (2015) · Cited by 28
Integrating Biological Networks for Drug Target Prediction and Prioritization
Ji, X., Freudenberg, J., & Agarwal, P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_12 · Cited by 20
AI in science: When and where it makes a difference
Bianchini, S., Girolamo, V. D., Ravet, J., & Arranz, D. (2026) · Research Policy · doi:10.1016/j.respol.2026.105478 · Cited by 23
Using median survival in meta-analysis of experimental time-to-event data
Hirst, T. C., Sena, E. S., & Macleod, M. R. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01824-0 · Cited by 20
“Page 3/15 However, translation of treatments from the preclinical to the clinical phase is known to be ine cient [5, 6].”
BackgroundFinancial intermediation and the funding of biomedical innovation: A review
Lo, A. W., & Thakor, R. T. (2023) · Journal of Financial Intermediation · doi:10.1016/j.jfi.2023.101028 · Cited by 24
Machine learning for metabolomics research in drug discovery
Martinelli, D. D. (2023) · Intelligence-Based Medicine · doi:10.1016/j.ibmed.2023.100101 · Cited by 23
Zhao, T., Wei, P., Zhang, C., Zhou, S., Liang, L., Guo, S., Yin, Z., Cheng, S., Gan, Z., Xia, Y., et al. (2023) · eLife · doi:10.7554/elife.90911 · Cited by 20
“However, the development and research of new drugs are time-consuming, costly, and uncertain ( Scannell et al., 2012 ), and exploring the potential indications of old drugs has been endorsed by scholars ( Wu, 2013 ).”
BackgroundDiscontinued drugs in 2011: oncology drugs
Williams, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.739605 · Cited by 19
Potential Strategies for Increasing Drug-Discovery Productivity
Cumming, J. G., Finlay, M. R. V., Giordanetto, F., Hemmerling, M., Lister, T., Sanganee, H. J., & Waring, M. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.7 · Cited by 20
Tang, H., Duggan, S., Richardson, P. L., Marin, V. L., Warder, S. E., & McLoughlin, S. M. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115622431 · Cited by 19
Guiding principles of value creation through collaborative innovation in pharmaceutical research
Schweizer, L., & He, J. Z. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.003 · Cited by 19
The impact of external innovation on new drug approvals: A retrospective analysis
Liu, X., Thomas, C. E., & Felder, C. C. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.093 · Cited by 20
“However, the efficiency of new launches as measured by the number of new FDA approved drugs per unit R&D expenditure has been declining for decades for the entire pharmaceutical industry [3].”
BackgroundEsposito, U., Das, R., Syed, S., Pirooznia, M., & Elhaik, E. (2018) · Genes · doi:10.3390/genes9120625 · Cited by 19
“In genetic association studies, mismatching cases 71 and controls introduces genetic heterogeneity that can lead to spurious associations and 72 obscure the true association [1, 2].”
BackgroundGrant, K., Matoušek, R., Meyer, M. S., & Tzeremes, N. (2019) · International Journal of Production Research · doi:10.1080/00207543.2019.1671623 · Cited by 19
“Scannell et al. (2012) estimate that the number of newly introduced drugs per billion U.S. dollars spent on R&D has halved every nine years since 1950.”
BackgroundMethodInfluential3D Engineering of Ocular Tissues for Disease Modeling and Drug Testing
Boutin, M. E., Hampton, C., Quinn, R., Ferrer, M., & Song, M. J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-28471-8_7 · Cited by 23
Chemically Defined Xeno- and Serum-Free Cell Culture Medium to Grow Human Adipose Stem Cells
Panella, S., Muoio, F., Jossen, V., Harder, Y., Eibl, R., & Tallone, T. (2021) · Cells · doi:10.3390/cells10020466 · Cited by 19
“Indeed, preclinical studies based on transformed animal cell lines, conventional cell culture conditions with undefined serum-containing media, and animal models have usually proven unable to predict drug efficacy in human trials [17,18].”
BackgroundStatistical refocusing in the design of Phase II trials offers promise of increased R&D productivity
Lindborg, S. R., Persinger, C. C., Sashegyi, A. I., Mallinckrodt, C. H., & Ruberg, S. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681-c1 · Cited by 19
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 21
“” The framework seeks to ensure continual review of all targets against the following criteria—right target, right patient, right tissue, right safety, and right commercial potential—and marks a move away from the volume-based measures of success that many see as contributing, in part, to the decline in industry produ…”
BackgroundApplying systems biology in drug discovery and development
Galizzi, J., Lockhart, B. P., & Bril, A. (2013) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2013-0002 · Cited by 19
Levaggi, R., & Pertile, P. (2019) · Applied Health Economics and Health Policy · doi:10.1007/s40258-019-00541-z · Cited by 19
“One explanation is that the natural growth in the quantity and quality of products available in the market raises the hurdle for new approvals [9].”
BackgroundRepurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy
Zhang, Y., Zheng, Q., Zhou, Y., & Liu, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00248 · Cited by 19
“Drugs have been proven to be indispensable for combating diseases and improving life quality, but the number of new drugs brought to the market has been declining (Scannell et al., 2012).”
BackgroundAI and the future of pharmaceutical researchPreprint
Zielinski, A. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.03896 · Cited by 20
“Cockburn (2006) raised two counter-points: first, that reported R&D expenditures are frequently overstated as they lack adjustment for inflation – an argument contradicted in the inflation-adjusted study by Scannell et al. (2012).”
BackgroundInfluentialBurt, T., Vuong, L. T., Baker, E., Young, G. C., McCartt, A. D., Bergstrom, M., Sugiyama, Y., & Combes, R. (2018) · Alternatives to Laboratory Animals · doi:10.1177/026119291804600603 · Cited by 18
A large-scale database for clinical trial outcomes and features
Gao, C., Pradeepkumar, J., Das, T., Thati, S., & Sun, J. (2026) · Nature Health · doi:10.1038/s44360-026-00081-6 · Cited by 18
Fatima, I., Ahmad, R., Barman, S., Gowrikumar, S., Pravoverov, K., Primeaux, M., Fisher, K. W., Singh, A. B., & Dhawan, P. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02570-x · Cited by 20
“Since such drugs have established safety pro fi les and pharmacokinetic properties, they can be quickly moved into clinical trials [9, 11].”
Graziano, E., Natho, P., Andresini, M., Mastrolorito, F., Mahdi, I., Mesto, E., Colella, M., Degennaro, L., Nicolotti, O., & Luisi, R. (2024) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202400781 · Cited by 23
Old drugs, new challenges: reassigning drugs for cancer therapies
Czechowicz, P., Więch, A., Sławski, J., Collawn, J. F., & Bartoszewski, R. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00710-0 · Cited by 22
“This limitation in R&D productivity is termed as ‘Eroom’s Law’ [11].”
Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3
Montero‐Melendez, T., Forfar, R., Cook, J. M., Jerman, J. C., Taylor, D. L., & Perretti, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2419-3 · Cited by 18
“The so-called Eroom’s law [38] refers to the decline in pharmaceutical R&D efficiency despite marked improvements in technology, where the cost of developing a new drug roughly doubles every 9 years.”
BackgroundThe translational potential of human induced pluripotent stem cells for clinical neurology
Devine, H. E., & Patani, R. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9372-7 · Cited by 19
“Some putative reasons for this failure include (i) selection of diseases where the molecular pathogenesis is poorly understood, this precluding a mechanistically rationalized approach (ii) over reliance on onemodel system or the use of models that have poor predictive value of clinical success (e.g., due to interspeci…”
BackgroundNetwork mirroring for drug repositioning
Park, S., Lee, D. A., & Shin, H. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0449-x · Cited by 18
“The whole processes for de novo drug discovery requires 10 ~ 17 years of period and tremendous cost of 300 ~ 600 million dollars, which is a deteriorated figure compared to 10 million dollar in 1970 and 100 million dollars in 2000 [3].”
BackgroundPatra, A. T., Hingamire, T., Belekar, M. A., Xiong, A., Subramanian, G., Bozdech, Z., Preiser, P. R., Shanmugam, D., & Chandramohanadas, R. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01802-19 · Cited by 18
“Pulling the Plug:” Time Allocation between Drug Discovery and Development Projects
Subramanian, A. M., Lévesque, M., & van de Vrande, V. (2020) · Production and Operations Management · doi:10.1111/poms.13255 · Cited by 19
“With R&D efficiency declining in the biopharma industry (Scannell et al. 2012, Schuhmacher et al. 2016), the question of how to allocate scarce resources is more compelling.”
BackgroundChoi, G., Kim, D., & Oh, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.660313 · Cited by 21
“Drug discovery costs are increasing and research and development efficiency is decreasing (Mak and Pichika, 2019) (Scannell et al., 2012) (Schuhmacher et al.”
BackgroundAbdelkarim, M., Pérez-Dávalos, L. A., Abdelkader, Y., Abostait, A., & Labouta, H. I. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2152000 · Cited by 20
Discovery Formulations: Approaches and Practices in Early Preclinical Development
Bhattachar, S., Bender, D. M., Sweetana, S. A., & Wesley, J. A. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1399-2_2 · Cited by 18
Daniel, G. W., Cazé, A., Romine, M. H., Audibert, C., Leff, J., & McClellan, M. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.1019 · Cited by 18
Development of Anti‐Inflammatory Drugs – the Research and Development Process
Knowles, R. G. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12130 · Cited by 18
Bygiene: The New Paradigm of Bidirectional Hygiene.
Al‐Ghalith, G. A., & Knights, D. (2015) · PubMed Central · Cited by 26
Evidence-Based Medicine as a Tool for Undergraduate Probability and Statistics Education
Masel, J., Humphrey, P. T., Blackburn, B., & Levine, J. (2015) · CBE—Life Sciences Education · doi:10.1187/cbe.15-04-0079 · Cited by 19
“…instruments has found that students' positive attitudes coming into a statistics course predicts their eventual performance in such a course and that attitudes improve only marginally following instruction (Elmore, 1993; Shultz and Koshino, 1998) or can even deteriorate (Schau and Emmioglu, 2012).”
BackgroundOverview of DNA repair pathways, current targets, and clinical trials bench to clinic
Kelley, M. R., & Fishel, M. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00001-2 · Cited by 21
Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology
Broes, S., Lacombe, D. A., Verlinden, M., & Huys, I. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00006 · Cited by 19
Evolutionary and genetic features of drug targets
Quan, Y., Wang, Z., Chu, X., & Zhang, H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21487 · Cited by 19
“In this newgeneage data, the human geneswas divided into eight classes according to their origins: (1) the commonancestor ofCellular organism, (2) the common ancestor of Eukaryota and Archaea (Euk_Archaea), (3) horizontal gene transfer from Bacteria (Euk + Bac), (4) Eukaryota, (5) Opisthokonta, (6) Eumetazoa, (7) Vert…”
BackgroundPreformulation in Drug Research and Pharmaceutical Product Development
Acharya, P. C., Shetty, S. R., Fernandes, C., Suares, D., Maheshwari, R., & Tekade, R. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814423-7.00001-0 · Cited by 26
Academia–industry Cooperation in the Medical Field: Matching Opportunities in Japan
Tsuruya, N., Kawashima, T., Shiozuka, M., Nakanishi, Y., & Sugiyama, D. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.010 · Cited by 18
Pal, R., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-63029-0 · Cited by 19
GeneDisco: A Benchmark for Experimental Design in Drug DiscoveryPreprint
Mehrjou, A., Soleymani, A., Jesson, A., Notin, P., Gal, Y., Bauer, S., & Schwab, P. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2110.11875 · Cited by 26
“…with (i) historically low probabilities of successful development into clinical-stage therapeutics (Hay et al., 2014; Wong et al., 2019), and, for many decades until recently (Ringel et al., 2020), (ii) declining industry productivity commonly referred to as “Eroom’s law” (Scannell et al., 2012).”
BackgroundArtificial Intelligence and Network Medicine: Path to Precision Medicine
Altucci, L., Badimón, L., Balligand, J., Baumbach, J., Catapano, A. L., Cheng, F., DeMeo, D. L., Gupta, R. M., Hacker, M., Liu, Y., et al. (2025) · NEJM AI · doi:10.1056/aira2401229 · Cited by 20
From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases
Hussain, M. S., Mir, P. A., Kumar, N., Mohi-ud-din, R., Wali, A. F., Mir, R. H., Talath, S., Sridhar, S. B., Shareef, J., Goud, M., et al. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/1070716 · Cited by 23
Strube, J., Ditz, R., Fröhlich, H., Köster, D., Grützner, T., Koch, J., & Schütte, R. (2014) · Chemie Ingenieur Technik · doi:10.1002/cite.201300081 · Cited by 17
Ibert, O., Jackson, G., Theel, T., & Vogelgsang, L. (2021) · Emerald Group Publishing Limited eBooks · doi:10.1108/s0733-558x20210000075010 · Cited by 17
Social media mining in drug development—Fundamentals and use cases
Koss, J., Rheinlaender, A., Truebel, H., & Bohnet-Joschko, S. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.012 · Cited by 17
Chen, H., Li, D., Liao, J., Wei, L., & Wei, L. (2022) · Methods · doi:10.1016/j.ymeth.2022.09.006 · Cited by 17
How to Accelerate R&D and Optimize Experiment Planning with Machine Learning and Data Science
Gutiérrez, D. P., Folkmann, L. M., Tribukait, H., & Roch, L. M. (2023) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2023.7 · Cited by 17
Advanced tissue engineering for in vitro drug safety testing
Owens, R. M. (2023) · MRS Communications · doi:10.1557/s43579-023-00421-7 · Cited by 20
“[22] Many people point to inefficiency in the drug discovery process with basic errors made in underappreciating physicochemical properties of drugs and underprediction of safety-related failures.”
BackgroundRepurposing FDA-approved compounds to target JAK2 for colon cancer treatment
Chandrasekhar, B., Gor, R., Ramalingam, S., Thiagarajan, A., Sohn, H., & Madhavan, T. (2024) · Discover Oncology · doi:10.1007/s12672-024-01050-9 · Cited by 17
The Emergence of Regulatory Science in Pharmaceutical Medicine
Callréus, T., & Schneider, C. K. (2013) · Pharmaceutical Medicine · doi:10.1007/s40290-013-0039-x · Cited by 17
“Against a backdrop of increasing costs and poor productivity [2, 3], the concept of ‘regulatory science’ has sometimes been invoked in recent years in discussions regarding regulation of pharmaceuticals.”
BackgroundThe academic–industrial complex: navigating the translational and cultural divide
Freedman, S. B., & Mullane, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.005 · Cited by 20
Time-Resolved Systems Medicine Reveals Viral Infection-Modulating Host Targets
Wiwie, C., Kuznetsova, I., Mostafa, A., Rauch, A., Haakonsson, A. K., Barrio‐Hernandez, I., Blagoev, B., Mandrup, S., Schmidt, H. H. H. W., Pleschka, S., et al. (2019) · Systems Medicine · doi:10.1089/sysm.2018.0013 · Cited by 17
Integrated Array Chip for High-Throughput Screening of Species Differences in Metabolism
Ai, X., Zhao, L., Lu, Y., Hou, Y., Lv, T., Jiang, Y., Tu, P., & Guo, X. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01590 · Cited by 17
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
Schuhmacher, A., Brieke, C., Gassmann, O., Hinder, M., & Hartl, D. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.06.015 · Cited by 23
Loskill, P., Hardwick, R. N., & Roth, A. B. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.08.004 · Cited by 17
“The literature is, however, rich in assessments of the shortcomings of the traditional drug development paradigm (Khanna, 2012; Kola and Landis, 2004; Paul et al., 2010; Scannell et al., 2012) as well as in proof-of-concept studies demonstrating the application of these novel models for different areas of drug discove…”
BackgroundTranslating Neurogenomics Into New Medicines
Wendland, J. R., & Ehlers, M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.027 · Cited by 17
Lead Discovery and Lead Modification
Silverman, R. B., & Holladay, M. W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-382030-3.00002-7 · Cited by 23
Hocker, H. J., Rambahal, N., & Gorfe, A. A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400474u · Cited by 18
Testing regimes in clinical trials: Evidence from four polio vaccine trajectories
Yaqub, O. (2016) · Research Policy · doi:10.1016/j.respol.2016.12.001 · Cited by 20
Mining the Genome for Therapeutic Targets
Florez, J. C. (2017) · Diabetes · doi:10.2337/dbi16-0069 · Cited by 17
Matteucci, C., Argaw-Denboba, A., Balestrieri, E., Giovinazzo, A., Miele, M. T., D’Agostini, C., Pica, F., Grelli, S., Paci, M., Mastino, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1474198 · Cited by 17
“growing productivity gap in the biopharmaceutical industry [1].”
BackgroundMizoguchi, R., & Uekusa, H. (2018) · Crystal Growth & Design · doi:10.1021/acs.cgd.8b01014 · Cited by 17
Cancer-on-a-chip for Drug Screening
Lee, I. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206235233 · Cited by 17
Nakajima, T., & Ikeya, M. (2019) · Regenerative Therapy · doi:10.1016/j.reth.2019.04.004 · Cited by 18
Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can … Now We Need to Start Pulling!
Rex, J. H., & Outterson, K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa852 · Cited by 17
Drug development and discovery: challenges and opportunities
Moridani, M. Y., & Harirforoosh, S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.003 · Cited by 17
Komarnisky, R.-M., Wootten, S., Friedman, N., & Nikkhah, M. (2025) · Lab on a Chip · doi:10.1039/d5lc00426h · Cited by 17
The Life Sciences Translational Challenge: The European Perspective
Barker, R., & Scannell, J. W. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014561340 · Cited by 18
“One widely quoted explanation, especially within the drug industry, is the depletion of ‘‘low hanging fruit’’ (although the precise nature of ‘‘fruit’’ is generally undefined).(1) Clearly, R&D in some disease areas (such as stomach ulcers) has become commercially exhausted, even if not technically or biologically exha…”
BackgroundMethodInfluentialSelf-citationAccessing external innovation in drug discovery and development
Tufféry, P. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1040759 · Cited by 16
“Accepting that the internally driven R&D model might become unsustainable, more open and externally driven ways of thinking are being considered [1-3].”
BackgroundUsing Human Genetics to Drive Drug Discovery: A Perspective
Fox, C. S. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.12.045 · Cited by 16
Therapeutic Drug Development and Human Clinical Trials
Kirsch, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815585-1.00024-3 · Cited by 16
A Review on Artificial Intelligence Approaches and Rational Approaches in Drug Discovery
Srivathsa, A. V., Sadashivappa, N. M., Hegde, A. K., Radha, S., Mahesh, A. R., Ammunje, D. N., Sen, D., Theivendren, P., Saravanan, G., Kunjiappan, S., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230428110542 · Cited by 20
Indian Berries and Their Active Compounds
Khan, M. S., Qais, F. A., & Ahmad, I. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814619-4.00008-2 · Cited by 16
Gurwitz, D. (2020) · Drug Development Research · doi:10.1002/ddr.21689 · Cited by 16
“The number of new drugs approved per billion US dollars spent for drug research and development was halved every 9 years since 1950, decreasing about 80-fold from 1950 to 2012 after adjustment for inflation (Scannell, Blanckley, Boldon, & Warrington, 2012).”
BackgroundNembo, E. N., Hescheler, J., & Nguemo, F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110730 · Cited by 18
Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury
Shakkour, Z., Habashy, K. J., Berro, M., Takkoush, S., Abdelhady, S., Koleilat, N., Eid, A. H., Zibara, K., Obeid, M., Shear, D., et al. (2020) · The Neuroscientist · doi:10.1177/1073858420961078 · Cited by 16
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.